Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.
Lixte enters new Collaborative Research Agreement with MD Anderson; pays milestone payments up to $1.5M ($500k per event) plus 3.75% royalty on net profit.
GSK and Lixte provide drugs at no cost to institution for expanded 42-patient study; no additional GSK payments beyond original 21 subjects.
Initial data from first 21 patients expected in first half of 2026; trial led by MD Anderson includes Northwestern as second site.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.